Tag Archive for: MIG Capital

SciRhom management: Jens Ruhe, COO, Jan Poth, CEO, und Matthias Schneider, CSO. © SciRhom/ Paul Paulsen
Series A financing

SciRhom GmbH closes €63m Series A financing

German iRhom2-targeted antibody specialist SciRhom GmbH has closed an oversubscribed €63m Series A financing that will be used to provide clinical proof of concept in autoimmune disorders.

Read more